Prevalence, incidence and mortality of hypertrophic cardiomyopathy based on a population cohort of 21.9 million in China

Ying Bai1, Jian-Peng Zheng2, Feng Lu2, Xi-Lin Zhang1, Chang-Ping Sun3,4, Wei-Hua Guo5, Yi-Xi Zou6, Gregory Y. H. Lip7,8 & Xu-Bo Shi1

There are limited studies on the prevalence and incidence of clinically diagnosed hypertrophic cardiomyopathy (HCM) and its mortality in the Chinese population, and the projected population burden of HCM over the next decades. We collected data on HCM and its mortality from the Beijing Municipal Health Commission Information Center (BMHCIC) database and estimated the prevalence and incidence based on the whole Beijing population. Calculation of population trends was performed using annual percentage change (APC) and average annual percentage change (AAPC). Finally, future HCM incidence was built by modelling projection of HCM to the next decades using Poisson regression analysis and Gray Model 1,1(GM [1,1]). The prevalence of HCM was 0.0069% (95%CI, 0.0065–0.0072%; N = 1343) in 2010, rising to 0.076% (95% CI, 0.074–0.077%; N = 16,616) in 2019, and the incidence of HCM was 6.85 per 100 000 person-year in 2010, rising to 11.76 per 100 000 person-year in 2019. Males had higher prevalence and incidence of HCM than females. The APPC for the rising incidence of HCM was 5.8% and the expected numbers will double increase in 2029 by assuming the same increase trend as the last decades. HCM had increased annual incidence of HF (APPC: 8.4, 4.4–12.6, p < 0.05), and relatively stable annual incidence of mortality (APPC: 1.2%, − 2.3% to 4.8%, p > 0.05) during the studied period. Males had lower mortality (2.70% vs. 4.20%, p < 0.001) than females. The calculated HCM prevalence was much lower compared to prior screening studies from 2004, although the predicted HCM incidence would double over the next decades. HCM was associated with a stable risk of mortality during the studied period.

The incidence of hypertrophic cardiomyopathy (HCM) varies widely around the world, ranging from 0.02 to 0.2% either in the western countries1–3 or in Asian countries4–7. HCM was considered as a genetic targeted disease developing either in childhood or in adulthood8,9, but was less identified unless symptoms occurred10,11. Therefore, the patients had less recognition of HCM before its symptoms and HCM was usually diagnosed when complications develop, such as heart failure (HF)12, stroke13, atrial fibrillation (AF)14 or sudden cardiac death.

Knowledge of the prevalence of HCM is important for exploring its impact on its associated complications, morbidity and mortality10,15,16. An increased prevalence and incidence of HCM in Asian countries in recent decades is probably due to methodological development in the echocardiographic interpretation of HCM and
increased clinical awareness or recognition. However, the prevalence has only been reported in a small numbers and limited age ranges.

There are few studies focusing on the change in HCM incidence in the Chinese population. In this registry study of 21.90 million Chinese population, we investigated the incidence of HCM in all age groups (0 to more than 100 years old) in China from 2010 to 2019. Second, we estimated the development of this disease with the estimation of the trends using annual percentage change (APC) and average annual percentage change (AAPC). Third, we explored the temporal incidence of HCM-related complications such as HF, AF, stroke and mortality.

Materials and methods

The current Beijing District consists of 8 urban areas and 8 suburban areas. The inhabitants ranged from 19.62 million in 2010 to 21.90 million in 2019 according to government reports (http://tjj.beijing.gov.cn).

Source of database. This whole Beijing population-based registry study used the Beijing Municipal Health Commission Information Center (BMHCIC) database. BMHCIC is a mandatory health surveillance and supervision government agency requiring the medical information uploaded from all the 153 hospitals/centers located in the overall Beijing area. The registry covered the demographics information including sex, age, ethnicity, registered date, registered center, contact information, variation of diseases and vital status during each hospitalization. The study protocol conformed to the ethical guidelines of the Declaration of Helsinki and was approved by the Ethical committee of Beijing Tongren Hospital, Capital Medical University. Informed consent was waived due to anonymized and unidentified information for the analysis.

Diagnosis of HCM cases and death. HCM was diagnosed according to the recommendations of American Heart Association (AHA). Patients with simple left ventricular hypertrophy (LVH), which did not conform to the HCM diagnosis criteria were excluded. The diagnosis was collected at each registry using the claims for diagnostic codes (International Classification of Diseases, Tenth Revision, Clinical Modification; ICD-10-CM) with I42.101 for obstructive HCM, I42.201 for unobstructive HCM, I42.202 for HCM (which was defined as undefined HCM in this study), and I42.203 for apical HCM. The diagnosis was established by cardiologists and sonographers for HCM (the clinical diagnostic data used in this study are shown in Supplementary Table 1), and then the accuracy was further validated by the experts invited by BMHCIC after being uploaded. The first time diagnosis with HCM was considered as the date of onset for the condition.

Statistics analysis. The prevalence of HCM was calculated using the cumulative number of survived HCM cases divided by the number of total populations in that referred year. The annual incidence of HCM was calculated with the number of newly diagnosed HCM cases divided by the population in that referred year and indicated as per 100,000 person-year. Mortality, rate of HF and rate of Implantable Cardioverter-defibrillator (ICD) implantation were calculated by dividing the events using the corresponding HCM number in that referred year. Comparisons of categorical variables were calculated using a chi-square test, while their change with year were calculated with Linear-by-Linear Association. The occurrence of incident HCM cases with year was assumed to conform to Poisson distribution and the time trends was evaluated with Joinpoint 4.9.0.0 (https://surveyine.cancer.gov/joinpoint/) with APC for each segment and AAPC for the whole trends. Incidence rate ratio (IRR) and 95% confidence interval (CI) of HCM cases with the potential effect of increased age and sex was calculated with the assumption of conforming to Poisson distribution. Poisson regression models and GM (1,1) were used to predict incident HCM cases in the next decades. Annual prevalence and incidence of subtypes of HCM (i.e. Apical HCM, obstructive HCM, unobstructive HCM and undefined HCM) were also calculated. SPSS, Matlab and Joinpoint software 4.9.0.0 were used for the calculation of the study. P value <0.05 was considered statistically significant.

Ethical statement. The study protocol conformed to the ethical guidelines of the Declaration of Helsinki and was approved by the Ethical committee of Beijing Tongren Hospital, Capital Medical University. Informed consent was waived due to anonymized and unidentified information for the analysis.

Results

In 2010, the overall prevalence of survived HCM survival was 0.0069% (95%CI, 0.0065–0.0072%; N = 1343) with 0.0081% (95%CI, 0.0076–0.0087%; N = 824) in males and 0.0055% (95%CI, 0.0050–0.0059%; N = 519) in females (Supplementary Table II). In 2019, the overall prevalence of survived HCM was up to 0.076% (95% CI, 0.074–0.077%; N = 16,616) with 0.094% (95% CI, 0.092–0.096%; N = 10,537) in the male, 0.057% (95% CI, 0.055–0.058%, N = 6079) in the female population and the ratio of males to females of 1.65:1 (Fig. 1) The prevalence of subtypes of HCM are shown in Fig. 1 as well.

From 2010 to 2019, a total of 17,085 newly diagnosed HCM were identified from the current registry, with an incidence increasing from 6.85 (6.48–7.21) in 2010 to 11.76 (11.30–12.21) in 2019 per 100 000 person-year (Table 1). Of these, the incidence of HCM increased with age overall, and in the male and female population. The incidence of HCM increased with age with the peak incidence in the age range of 80 to 84 years after adjustment of sex using Poisson distribution analysis as shown in Fig. 2. The age-specific incidence also increased with age in males (Supplementary Fig. IA) and females (Supplementary Fig. IB). The IRR of males to females was 1.73 (95% CI: 1.68–1.79) based on Poisson distribution analysis after adjustment of age.

The annual incidence of subtypes of HCM is shown in Supplementary Table III. This showed newly diagnosed apical HCM rising from 0.46(0.36,0.55) to 1.17(1.03,1.31), obstructive HCM from 2.22(2.01,2.43) to
Figure 1. Prevalence of hypertrophic cardiomyopathy and its subtypes in 2019 in the total, males and females. HCM, hypertrophic cardiomyopathy.

| Year | Newly diagnosed HCM cases | Population | Incidence (95% CI) Per 100 000 person-years |
|------|---------------------------|------------|---------------------------------------------|
|      |                           |            | Total                                        |
| 2010 | 1343                      | 19,612,368 | 6.85 (6.48, 7.21)                            |
| 2011 | 1320                      | 20,231,159 | 6.52 (6.17, 6.88)                            |
| 2012 | 1368                      | 20,767,977 | 6.59 (6.24, 6.94)                            |
| 2013 | 1344                      | 21,246,815 | 6.33 (5.99, 6.66)                            |
| 2014 | 1479                      | 21,703,661 | 6.81 (6.47, 7.16)                            |
| 2015 | 1659                      | 21,875,603 | 7.58 (7.22, 7.95)                            |
| 2016 | 1829                      | 21,957,103 | 8.33 (7.95, 8.71)                            |
| 2017 | 1989                      | 21,947,103 | 9.06 (8.66, 9.46)                            |
| 2018 | 2179                      | 21,920,099 | 9.94 (9.52, 10.36)                           |
| 2019 | 2575                      | 21,904,097 | 11.76 (11.3, 12.21)                          |
|      |                           |            | Males                                        |
| 2010 | 824                       | 10,126,430 | 8.14 (7.58, 8.69)                            |
| 2011 | 841                       | 10,318,297 | 8.15 (7.60, 8.70)                            |
| 2012 | 875                       | 10,733,216 | 8.15 (7.61, 8.69)                            |
| 2013 | 833                       | 10,975,131 | 7.59 (7.07, 8.11)                            |
| 2014 | 912                       | 11,184,057 | 8.15 (7.63, 8.68)                            |
| 2015 | 994                       | 11,258,031 | 8.83 (8.28, 9.38)                            |
| 2016 | 1203                      | 11,262,398 | 10.68 (10.08, 11.29)                         |
| 2017 | 1273                      | 11,240,396 | 11.33 (10.7, 11.95)                          |
| 2018 | 1396                      | 11,223,394 | 12.44 (11.79, 13.09)                         |
| 2019 | 1629                      | 11,206,391 | 14.54 (13.83, 15.24)                         |
|      |                           |            | Females                                      |
| 2010 | 519                       | 9,483,938  | 5.47 (5.00, 5.94)                            |
| 2011 | 479                       | 9,912,861  | 4.83 (4.40, 5.26)                            |
| 2012 | 493                       | 10,034,761 | 4.91 (4.48, 5.35)                            |
| 2013 | 511                       | 10,271,684 | 4.97 (4.54, 5.41)                            |
| 2014 | 567                       | 10,519,694 | 5.39 (4.95, 5.83)                            |
| 2015 | 665                       | 10,617,573 | 6.26 (5.79, 6.74)                            |
| 2016 | 626                       | 10,694,705 | 5.85 (5.39, 6.31)                            |
| 2017 | 716                       | 10,706,706 | 6.69 (6.20, 7.18)                            |
| 2018 | 783                       | 10,696,705 | 7.32 (6.81, 7.83)                            |
| 2019 | 946                       | 10,697,705 | 8.84 (8.28, 9.41)                            |

Table 1. Incidence of hypertrophic cardiomyopathy. HCM hypertrophic cardiomyopathy.
4.62(4.34,4.91) and unobstructive HCM from 1.25(1.09,1.41) to 1.95(1.77,2.14) and undefined HCM from 2.92(2.68,3.16) to 4.01(3.74,4.27).

Incidence rate ratio of subtypes of HCM with ageing was shown in Supplementary Fig. II, which showed the higher IRR in the relatively elder age range.

The IRR of males to females had a range of 1.29:1 to 2.40:1 after the adjustment of age according to Poisson distribution analysis (Supplementary Table IV).

Temporal trends from 2010 to 2019. As shown in Table 2, the increasing trends were seen in overall (AAPC = 5.8%, \( p < 0.05 \)), and amongst males (AAPC = 6.6%, \( p < 0.05 \)) and females (AAPC = 5.3%, \( p < 0.05 \)) from 2010 to 2019. The APC slightly decreased since 2010 to 2013 and sharply increased from 2013 to 2019 in overall and amongst males and females (all \( p < 0.05 \)). The AAPC for the total population increased to 7.0 and the AAPC increased in males to 7.4 and females to 6.3 (All \( p < 0.05 \)).

We calculated temporal trends by categorized age of 0–9 years, 10–29 years, 30–59 years and \( \geq 60 \) years and found the AAPC showed increasing trends in all the subtypes of HCM of overall.

| Year Range | Joinpoint | APC (95% CI) | p value | AAPC (95% CI) | p value |
|------------|-----------|--------------|---------|--------------|---------|
| **Hypertrophic cardiomyopathy** | | | | | |
| Total      | 2010–2013 | 1            | −3.2 (−8.5–2.5) | >0.05 | |
|            | 2013–2019 | 1            | 10.5 (8.8–12.3) | <0.05 | |
|            | 2010–2019 | 1            | 5.8 (4.0–7.5)   | \( p < 0.05 \) | |
|            | 2010–2019 | 0            | 7.0 (4.5–9.4)   | \( p < 0.05 \) | |
| Males      | 2010–2014 | 1            | −0.3 (−4.7–4.3) | >0.05 | |
|            | 2014–2019 | 1            | 12.5 (9.6–15.4) | <0.05 | |
|            | 2010–2019 | 1            | 6.6 (4.6–8.6)   | \( p < 0.05 \) | |
|            | 2010–2019 | 0            | 7.4 (4.7–10.1)  | \( p < 0.05 \) | |
| Females    | 2010–2013 | 1            | −2.7 (−15.6–12.1) | >0.05 | |
|            | 2013–2019 | 1            | 9.5 (5.2–14.0)  | <0.05 | |
|            | 2010–2019 | 1            | 5.3 (1.0–9.7)   | \( p < 0.05 \) | |
|            | 2010–2019 | 0            | 6.3 (3.7–8.9)   | \( p < 0.05 \) | |
| 0–9 years old | 2010–2019 | 0            | −4.8 (−13.1–3.3) | >0.05 | |
| 10–29 years old | 2010–2019 | 0            | 25.3 (20.9–29.9) | <0.05 | |
| 30–59 years old | 2010–2019 | 0            | 6.9 (5.2–8.7)   | <0.05 | |
| 60+ years old | 2010–2019 | 0            | −1.6 (−4.7–1.6) | >0.05 | |
| **Death in hypertrophic cardiomyopathy** | | | | | |
| Total      | 2010–2019 | 0            | 1.2 (−2.3–4.8)  | >0.05 | |
| Males      | 2010–2019 | 0            | 1.5 (−2.5–5.7)  | >0.05 | |
| Females    | 2010–2019 | 0            | 0.4 (−6.0–7.2)  | >0.05 | |
Prediction of new cases of HCM beyond 2019. Similar results were obtained using both Poisson regression analysis and GM (1,1) for the modelling prediction of new cases of HCM beyond 2019 based on the assumption that HCM incidence kept the same increasing trend. Figure 3 and Table 3 shows a 2.19-fold (Incidence rate in 2029: 20.57, 95%CI: 20.44–21.56) increase in incident HCM cases by 2029 using Poisson regression analysis and a 2.48-fold (Incidence rate in 2019: 24.78, 95%CI: 24.38–25.62) increase in 2029 using GM (1,1).

The modeling projections of the subtypes of incident HCM cases (including apical HCM, obstructive HCM, unobstructive HCM and undefined HCM) are shown in Supplementary Fig. III. and the estimated predicting numbers of incidence of subtypes of HCM cases are shown in Supplementary Table VI. This showed two to three-fold increase of incident HCM by 2029 compared to 2019.

Incidence of mortality in HCM. Percentages of death are described in Supplementary Fig. IV. Of 17,085 HCM cases, 3.26% (N = 556) died during the studied time period. The overall mortality for HCM increased from 2.38% (N = 32) in 2010 to 3.38% (N = 87) in 2019. The mortality was stable in each year (p < 0.001) while the incidence of HF increased from 2010 to 2019 in overall, and amongst males and females (Table 2). No significant change could be seen for the mortality in the first (3.15%, N = 216) and last five years (3.32%, N = 340, p = 0.56). Males had a lower mortality (2.70% vs. 4.20%, p < 0.001) compared to females (Supplementary Table VII). One thousand and sixty-six (6.24%) of them experienced ventricular tachycardia or fibrillation from 2010 to 2019, keeping stable from 2010 to 2019 (p = 0.25). We also found that 1.40% (N = 239) of HCM patients received ICD over the past 10 years, and the implantation rate increased from 0.74% (N = 10) in 2010 to 1.32% (N = 34) in 2019, showing an overall upward trend (p = 0.25). In our study, the mortality of patients with ICD implantation was 3.35% (N = 8), while the mortality of patients without ICD implantation was 3.25% (N = 548), which did not show statistical significance (p = 0.85) (Supplementary Table VIII).

Discussion
In this study, our principal findings are as follows: (i) The prevalence of HCM was 0.0069% in 2010 and rising to 0.076% in 2019, and the rising incidence of 6.85 per 1000 000 person-year in 2010 to 11.76 per 1000 000 person-year in 2019; (ii) the AAPC for the rising incidence of HCM was 5.8% and the expected number will

**Figure 3.** Projected modelling of hypertrophic cardiomyopathy to the next decades. HCM hypertrophic myocardiopathy.

**Table 3.** Modelling predicted number of hypertrophic myocardiopathy over the next decades. For Gray model (1,1) analysis, the P value is 1 and the C value is 0.19.
double by 2029; (iii) HCM had stable mortality during the studied period; and (iv) males had a lower mortality compared to females.

Almost 20 years ago, the estimated prevalence of HCM was reported of 0.2%, which was based on the CARDIA (Coronary Artery Risk Development in Young Adults) cohort study originally collecting information of people aged 23 to 35 years using phenotype-based echocardiographic examinations. Furthermore, HCM-causing pathogenic mutations involving sarcomere mutations suggested a prevalence of 0.5% or greater. An earlier HCM screening study in patients age 18–74 years old found a prevalence of HCM of 0.16% in China. We speculated that the differences of prevalence between our study and previous studies were mainly caused by the different studied populations, though our research methods were similar to some studies. We used the data from the real-world administrative data, rather than screening specifically for HCM, and confirmed the detected HCM incidence remained low in the Chinese population, as the prevalence of HCM was 0.076% of our 21.90 million population covering all ages. Besides, our study involved all the centers around the whole Beijing district, the metropolis where the inhabitants come from all over the country. Furthermore, this study involved diverse racial residents in the area of Beijing.

The smaller prevalence of HCM than previous studies suggests that the diagnosis was much lower than expected. Data of BMHCIC provide robust evidence for the epidemiological status of clinically relevant HCM in the last decades. Unidentified HCM is likely to greater, since the diagnosis of HCM was largely dependent on the clinical manifestation and the willing to seek medication of the patients. We also found that the mortality in our study was higher than in previous studies (about 1% per year). Unfortunately, our high mortality is not related to ICD implantation.

This is the first study revealing a rising trend of HCM incidence in the Chinese population, similar to the rising prevalence noted in Korea over the last decades. The incidence of HCM showed an increasing trend by AAPC from 2010 to 2019, and such increase trends were found both in males and females. However, this increase trend vanished when the analysis was restricted to the age range of 0–9 years and older than 60 years. The increased incidence risk of HCM with ageing was reported previously. This phenomenon of rapid rising HCM incidence in the social active population of age ranging from 10 to 59 years old may provide some clues that the rising HCM mutation can be related to the rapid economy development, environmental and lifestyle changes in Asia in recent years.

By assuming the same increase trend over the next decades, we explored the possible future HCM number and incidence. The clinical diagnosis of HCM can perhaps be considered as “the tip of the iceberg of the disease spectrum” indicating an underestimation of the incidence of HCM. Subtypes of HCM had broadly similar trends with ageing to the incidence of overall HCM. Their current status and modelling projections to the next decades were mostly consistent with the overall data for HCM.

**Limitations.** There are some limitations to be mentioned for the current study. Like some studies investigating HCM prevalence, we used clinically diagnosed data mostly by echocardiographic examinations or CMR results and only a minority of the patients had genetic examination results. Second, because not all the admitted patients had echo-cardiography examinations, the lower prevalence than previous studies may indicated a lower identification rate of HCM in China. Therefore, raising attention to the HCM screening is necessary to reduce their complications, such as heart failure, stroke or even sudden cardiac death. Third, this study was not specifically designed as a screening study for HCM.

**Conclusions**

The calculated HCM prevalence was much lower compared to prior screening studies from 2004, although the predicted HCM incidence would double over the next decades. HCM was associated with a stable mortality during the studied period.

**Data availability**

All data generated or analysed during this study are included in this published article and its supplementary information files.

Received: 29 March 2022; Accepted: 7 September 2022
Published online: 05 November 2022

**References**

1. Codd, M. B., Sugrue, D. D., Gersh, B. J. & Melton, L. J. 3rd. Epidemiology of idiopathic dilated and hypertrophic cardiomyopathy. A population-based study in olmsted county, minnesota, 1975–1984. Circulation 80, 564–572 (1989).
2. Maron, M. S., Hellawell, J. L., Lucove, J. C., Farzaneh-Far, R. & Olivetto, I. Occurrence of clinically diagnosed hypertrophic cardiomyopathy in the united states. Am. J. Cardiol. 117, 1651–1654 (2016).
3. Maron, B. J. et al. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the cardia study. Coronary artery risk development in (young) adults. Circulation 92, 785–789 (1995).
4. Miura, K. et al. Epidemiology of idiopathic cardiomyopathy in Japan: Results from a nationwide survey. Heart (Brit. Cardiac. Soc.) 87, 126–130 (2002).
5. Hada, Y. et al. Prevalence of hypertrophic cardiomyopathy in a population of adult Japanese workers as detected by echocardiographic screening. Am. J. Cardiol. 59, 183–184 (1987).
6. Moon, I., Lee, S. Y. & Kim, H. K. Trends of the prevalence and incidence of hypertrophic cardiomyopathy in Korea: A nationwide population-based cohort study. PLoS ONE 15, e0227012 (2020).
7. Zou, Y. et al. Prevalence of idiopathic hypertrophic cardiomyopathy in china: A population-based echocardiographic analysis of 8080 adults. Am. J. Med. 116, 14–18 (2004).
8. Bick, A. G. et al. Burden of rare sarcomere gene variants in the framingham and jackson heart study cohorts. Am. J. Hum. Genet. 91, 513–519 (2012).
9. Maron, B. J., Maron, M. S. & Semsarian, C. Genetics of hypertrophic cardiomyopathy after 20 years: Clinical perspectives. J. Am. Coll. Cardiol. 60, 705–715 (2012).
10. Maron, B. J. Clinical course and management of hypertrophic cardiomyopathy. N. Engl. J. Med. 379, 655–668 (2018).
11. Semsarian, C., Ingles, J., Maron, M. S. & Maron, B. J. New perspectives on the prevalence of hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 65, 1249–1254 (2015).
12. Maron, B. J., Rowin, E. J., Udelson, J. E. & Maron, M. S. Clinical spectrum and management of heart failure in hypertrophic cardiomyopathy. JACC. Heart failure. 6, 353–363 (2018).
13. Fauchier, L. et al. Ischemic stroke in patients with hypertrophic cardiomyopathy according to presence or absence of atrial fibrillation. Stroke 53, 497–504 (2022).
14. Garg, L. et al. Atrial fibrillation in hypertrophic cardiomyopathy: Prevalence, clinical impact, and management. Heart Fail. Rev. 24, 189–197 (2019).
15. Maron, B. J. Hypertrophic cardiomyopathy: A systematic review. JAMA 287, 1308–1320 (2002).
16. Maron, B. J. & Maron, M. S. Hypertrophic cardiomyopathy. Lancet (Lond. Engl.) 381, 242–255 (2013).
17. Ommen, S. R. et al. 2020 aha/acc guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: Executive summary: A report of the american college of cardiology/american heart association joint committee on clinical practice guidelines. Circulation 142, e533–e557 (2020).
18. Kim, H. J., Fay, M. P., Feuer, E. J. & Midthune, D. N. Permutation tests for joinpoint regression with applications to cancer rates. Stat. Med. 19, 335–351 (2000).
19. Hu, Y. C. A genetic-algorithm-based remnant grey prediction model for energy demand forecasting. PLoS ONE 12, e0185478 (2017).
20. Seidman, J. G. & Seidman, C. The genetic basis for cardiomyopathy: From mutation identification to mechanistic paradigms. Cell 104, 557–567 (2001).
21. MacArthur, D. G. et al. Guidelines for investigating causality of sequence variants in human disease. Nature 508, 469–476 (2014).
22. Husser, D. et al. Prevalence of clinically apparent hypertrophic cardiomyopathy in germany-an analysis of over 5 million patients. PLoS ONE 13, e0196612 (2018).

Author contributions
Y.B. wrote the main manuscript, W.H.G. and C.P.S. prepared figures. X.L.Z., J.P.Z. and F.L. extracted data. All authors reviewed the manuscript.

Funding
This study was supported by the grants from Beijing Municipal Administration of Hospitals’ Youth Programme (QML20180207).

Competing interests
The authors declare no competing interests.

Additional information
Supplementary Information The online version contains supplementary material available at https://doi.org/10.1038/s41598-022-20042-9.

Correspondence and requests for materials should be addressed to Y.B. or X.-B.S.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022